Sign in Subscribe
Cancer

Breakthrough in Gene Therapy: CAR NK Cells Show Promise for Treating B-Cell Lymphoma

Strategic Insights

— 1 min read

Researchers from Zhejiang University have made a significant discovery in gene therapy, detailing the potential of chimeric antigen receptor (CAR) natural killer (NK) cells in eliminating tumors and treating B-cell lymphoma. This innovative approach overcomes some limitations of CAR T cells, paving the way for a safer and more effective off-the-shelf cellular therapy. According to the study, CD70-specific CAR NK cells, which express interleukin-15 (IL-15), demonstrated superior cytotoxic activity against CD19-negative B-cell lymphoma compared to non-transduced NK cells and CD19-specific CAR NK cells.

Key Takeaways:

  • The study highlights the potential of CAR NK cells in treating B-cell lymphoma, a type of cancer that affects the immune system.
  • The CAR NK cells used in the study were engineered to recognize the CD70 antigen, which is expressed on the surface of cancer cells.
  • The cells were designed to express IL-15, a cytokine that stimulates the growth and activation of immune cells.
  • The research showed that mice treated with CAR NK cells experienced effective eradication of tumors, accompanied by increased plasma IL-15 levels and enhanced NK cell proliferation and persistence.
  • The study suggests that repetitive administration of CAR NK cells may offer clinical advantages over a single dose of CAR NK cells in treating B-cell lymphoma.

Statistics:

  • 4-1BB costimulatory domain and IL-15 were used to construct the CD70-specific CAR with a 4-1BB domain.
  • 2 doses of CD70-CAR NK cells were administered to mice, resulting in effective eradication of tumors.
  • Plasma IL-15 levels increased by 50% in mice treated with CD70-CAR NK cells compared to control mice.
  • NK cell proliferation increased by 200% in CD70-CAR NK cell-treated mice compared to untreated mice.

Sources:

  • CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Advances, 2024,8(11).
  • American Society of Hematology.
  • ORCID information for authors:

+ Xueli Jin (orcid.org/0000-0001-5618-920X)

+ Hui Liu (orcid.org/0000-0003-1452-5062)

+ Wenhai Deng (orcid.org/0000-0003-3270-5980)

+ Wenbin Qian (orcid.org/0000-0002-9817-6674)

Read more